Published in Nat Rev Nephrol on April 01, 2009
Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol (2010) 4.59
Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med (2008) 3.72
Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med (2008) 2.11
Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis (2008) 1.38
State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich) (2008) 1.38
Strategies for improvement of awareness, treatment and control of hypertension: results of a panel discussion. J Hum Hypertens (2004) 1.01
Analyzing the radial pulse waveform: narrowing the gap between blood pressure and outcomes. Curr Opin Nephrol Hypertens (2007) 1.01
Prevalence and correlates of left ventricular hypertrophy in the African American Study of Kidney Disease Cohort Study. Hypertension (2007) 0.99
Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia. Kidney Int Suppl (2005) 0.99
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med (2011) 11.11
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Nephron number in patients with primary hypertension. N Engl J Med (2003) 6.74
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol (2009) 4.31
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension (2006) 3.89
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 3.48
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem (2011) 2.82
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int (2005) 2.78
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 2.75
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis (2003) 2.68
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant (2010) 2.64
Essential hypertension. Lancet (2007) 2.63
Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol (2008) 2.63
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43
The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab (2008) 2.34
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med (2012) 2.24
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2010) 2.18
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med (2007) 2.14
Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol (2009) 2.13
Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol (2010) 2.13
Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med (2008) 2.11
Preparation of the dialysis patient for transplantation. Nephrol Dial Transplant (2002) 2.10
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 2.00
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol (2005) 1.96
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem (2010) 1.95
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J (2012) 1.95
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2011) 1.88
1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol (2003) 1.86
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
Nutritional status in dialysis patients: a European consensus. Nephrol Dial Transplant (2002) 1.81
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med (2005) 1.76
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol (2005) 1.74
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med (2002) 1.73
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J (2010) 1.72
Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 1.71
Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant (2011) 1.71
Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol (2002) 1.70
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol (2002) 1.70
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension (2011) 1.69
G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens (2009) 1.66
The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney Int (2013) 1.65
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int (2012) 1.65
Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation (2003) 1.63
A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int (2008) 1.61
Body weight changes with beta-blocker use: results from GEMINI. Am J Med (2007) 1.60
Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant (2013) 1.55
Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J (2011) 1.55
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA (2013) 1.54
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens (Greenwich) (2009) 1.54
World Kidney Day 2016: Averting the legacy of kidney disease-focus on childhood. Pediatr Nephrol (2016) 1.52
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press (2007) 1.52
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis (2009) 1.52
Combination therapy in hypertension. J Am Soc Hypertens (2010) 1.51
Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int (2011) 1.51
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) (2007) 1.50
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail (2010) 1.50
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press (2005) 1.49
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol (2008) 1.48
Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta (2010) 1.46
High salt intake causes adverse fetal programming--vascular effects beyond blood pressure. Nephrol Dial Transplant (2012) 1.46
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension (2008) 1.46
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J (2008) 1.46
No aggravation of renal injury in apolipoprotein E knockout mice (ApoE(-/-)) after subtotal nephrectomy. Nephrol Dial Transplant (2004) 1.45
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) (2011) 1.44
High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens (2004) 1.43
Salt-sensitive blood pressure--an intermediate phenotype predisposing to diabetic nephropathy? Nephrol Dial Transplant (2005) 1.40
The living kidney donor: giving life, avoiding harm. Nephrol Dial Transplant (2003) 1.40
Acute phase reaction to gadolinium-DTPA in dialysis patients. Nephrol Dial Transplant (2008) 1.39
Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol (2003) 1.39
State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich) (2008) 1.38
Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. J Womens Health (Larchmt) (2012) 1.38